The Australian Cystic Fibrosis Research Trust (ACFRT) is delighted to announce The David Millar Giles Innovation Grant to fund innovative research in cystic fibrosis (CF) with a focus on rare mutations. This grant will be awarded to one applicant for one year and will be managed by Cystic Fibrosis Australia (CFA).
The David Millar Giles Innovation Grant will allow a researcher to explore novel concepts at the initial feasibility stage. Innovative applications that particularly focus on research into rare mutations in CF are welcome, even those lacking pilot data. This grant aims to fund the researcher to generate sufficient data within the one-year period to be in a position to apply for additional support from an appropriate funding body to continue the research.
The Innovation Grant focusing on ‘rare mutations in CF’ will be offered to post doctoral researchers currently working in or proposing to work in CF or genetic research. The researcher will have completed a research higher degree in CF or a related area within the last ten years.
The recipient of the David Millar Giles Innovation Grant is required to provide progress reports on their research to CFA every six months. In addition, and where appropriate, the recipient will be asked to make a presentation at a CFA conference (held every 2 years) in Australia.
The maximum amount awarded under the Grant will $45,000. The actual amount provided will be subject to approval of the applicant’s budget.
Applications must be sent to the Research Manager. [email protected] by 17:00 AEDST, 3rd April 2019. https://www.cysticfibrosis.org.au/research/grants
Please contact Nicki Mileham if you have any questions regarding the David Miller Giles Grant or any other Australian Cystic Fibrosis Research Trust grant. [email protected]